ATE437943T1 - Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. - Google Patents

Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.

Info

Publication number: ATE437943T1
Authority: AT; Austria
Prior art keywords: gene expression; recombinant gene; antigen; vectors; expression vectors
Prior art date: 1996-01-30

Application number

AT97903998T

Other languages

English (en)

Inventor

Dennis Carson

Eyal Raz

Mark Roman

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-30

Filing date

1997-01-28

Publication date

2009-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24375188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437943(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-01-28 Application filed by Univ California filed Critical Univ California

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE437943T1 publication Critical patent/ATE437943T1/de

Links

239000013604 expression vector Substances 0.000 title abstract 7
238000000034 method Methods 0.000 title abstract 4
230000028993 immune response Effects 0.000 title 1
230000014509 gene expression Effects 0.000 abstract 6
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
230000003308 immunostimulating effect Effects 0.000 abstract 3
108091033319 polynucleotide Proteins 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 3
239000002157 polynucleotide Substances 0.000 abstract 3
108020004414 DNA Proteins 0.000 abstract 2
102000053602 DNA Human genes 0.000 abstract 2
241000700605 Viruses Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
210000001519 tissue Anatomy 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
108020004682 Single-Stranded DNA Proteins 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
210000004877 mucosa Anatomy 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1
239000003981 vehicle Substances 0.000 abstract 1
229960004854 viral vaccine Drugs 0.000 abstract 1
239000013603 viral vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Virology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT97903998T 1996-01-30 1997-01-28 Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. ATE437943T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US59355496A	1996-01-30	1996-01-30
PCT/US1997/001277 WO1997028259A1 (en)	1996-01-30	1997-01-28	Gene expression vectors which generate an antigen specific immune response and methods of using the same

Publications (1)

Publication Number	Publication Date
ATE437943T1 true ATE437943T1 (de)	2009-08-15

Family

ID=24375188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97903998T ATE437943T1 (de)	1996-01-30	1997-01-28	Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.

Country Status (7)

Country	Link
US (1)	US20030203861A1 (de)
EP (1)	EP0879284B1 (de)
JP (1)	JP4359654B2 (de)
AT (1)	ATE437943T1 (de)
CA (1)	CA2244946C (de)
DE (1)	DE69739515D1 (de)
WO (1)	WO1997028259A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2711670B1 (fr)	1993-10-22	1996-01-12	Pasteur Institut	Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
JP4111403B2 (ja)	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en) *	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE421888T1 (de) *	1997-08-13	2009-02-15	Uab Research Foundation	Impfung durch topische verwendung genetischer vektoren
DK1009413T3 (da) *	1997-09-05	2007-06-11	Univ California	Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999058118A2 (en) *	1998-05-14	1999-11-18	Cpg Immunopharmaceuticals Gmbh	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1733735T3 (en)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Methods and products for the induction of mucosal immunity
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
AU4343700A (en)	1999-04-12	2000-11-14	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US7479285B1 (en)	1999-08-19	2009-01-20	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU1013601A (en) *	1999-10-22	2001-05-08	Aventis Pasteur Limited	Method of inducing and/or enhancing an immune response to tumor antigens
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
EP1322655B1 (de)	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2001055341A2 (en)	2000-01-31	2001-08-02	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
WO2001097843A2 (en)	2000-06-22	2001-12-27	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
NZ526322A (en)	2000-12-27	2005-06-24	Dynavax Tech Corp	Immunomodulatory polynucleotides and methods of using the same
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
EP1404873B1 (de)	2001-06-21	2013-05-22	Dynavax Technologies Corporation	Chimäre immunmodulatorische verbindungen und verfahren zu deren verwendung
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456328C (en)	2001-08-07	2015-05-26	Dynavax Technologies Corporation	Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
EP1450856B1 (de)	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) *	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP1551376A4 (de)	2002-08-12	2010-10-06	Dynavax Tech Corp	Immunomodulatorische zusammensetzungen, herstellungsverfahren und verwendungsverfahren dafür
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CA2503693A1 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1572122A4 (de)	2002-11-01	2008-04-09	Us Gov Health & Human Serv	Verfahren zur vorbeugung gegen infektionen von bioterrorismus-agentien mit immunstimulierenden cpg-oligonukleotiden
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
ATE544772T1 (de)	2002-12-23	2012-02-15	Dynavax Tech Corp	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
RU2351362C2 (ru)	2003-03-26	2009-04-10	Цитос Байотекнолоджи Аг	КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
SG160336A1 (en)	2005-03-04	2010-04-29	Dynavax Tech Corp	Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
US8642577B2 (en)	2005-04-08	2014-02-04	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
EP1904077B1 (de)	2005-07-01	2009-08-12	Index Pharmaceuticals AB	Modulierung der reaktion auf steroide
DK2380584T3 (da)	2005-07-01	2014-01-20	Index Pharmaceuticals Ab	Immunstimulerende fremgangsmåde
WO2007050034A1 (en)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
WO2007068747A1 (en)	2005-12-14	2007-06-21	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
AU2007268534B2 (en) *	2006-05-31	2011-07-14	Osaka University	Immunostimulatory oligonucleotide and pharmaceutical application thereof
JP5437797B2 (ja)	2006-06-12	2014-03-12	サイトスバイオテクノロジーアーゲー	Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
CA2669137A1 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
US8815817B2 (en)	2008-05-15	2014-08-26	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
CA2748788C (en)	2009-01-05	2021-02-09	Epitogenesis Inc.	The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
MX2011007494A (es) *	2009-01-13	2011-08-12	Transgene Sa	Uso de una fraccion de la mitocondria de acidos nucleicos de saccharomyces cerevisiae para la estimulacion inmune.
PT2534150T (pt)	2010-02-12	2017-05-02	Chimerix Inc	Métodos para tratar uma infecção viral
JP2013521002A (ja)	2010-03-05	2013-06-10	プレジデントアンドフェロウズオブハーバードカレッジ	誘導樹状細胞組成物及びその使用
EP2596806A1 (de)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Verfahren zur Vorbeugung einer Dickdarmresektion
US9717657B2 (en)	2012-10-24	2017-08-01	Amy Dukoff	Composition and method of using medicament for endodontic irrigation, stem cell preparations and tissue regeneration
ES2762631T3 (es)	2013-03-14	2020-05-25	Harvard College	Composiciones a base de nanopartículas
EP3892284B1 (de)	2015-05-29	2024-05-22	Merck Sharp & Dohme LLC	Kombination aus einem pd-1-antagonist und cpg-c-typ-oligonukleotid zur behandlung von krebs
WO2023081486A1 (en)	2021-11-08	2023-05-11	Nurix Therapeutics, Inc.	Toll-like receptor therapy combinations with cbl-b inhibitor compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3596660A (en) *	1969-05-12	1971-08-03	Illinois Tool Works	Injection device
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US5985847A (en) *	1993-08-26	1999-11-16	The Regents Of The University Of California	Devices for administration of naked polynucleotides which encode biologically active peptides
US20030109469A1 (en) *	1993-08-26	2003-06-12	Carson Dennis A.	Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
JP4111403B2 (ja) *	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) *	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU7690898A (en) *	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
DK1009413T3 (da) *	1997-09-05	2007-06-11	Univ California	Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US20030138808A1 (en) *	1998-02-19	2003-07-24	Simard John J.L.	Expression vectors encoding epitopes of target-associated antigens
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999058118A2 (en) *	1998-05-14	1999-11-18	Cpg Immunopharmaceuticals Gmbh	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6887464B1 (en) *	1999-02-02	2005-05-03	Biocache Pharmaceuticals, Inc.	Advanced antigen presentation platform
US6514948B1 (en) *	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
WO2001055341A2 (en) *	2000-01-31	2001-08-02	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001062207A2 (en) *	2000-02-23	2001-08-30	The Regents Of The University Of California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) *	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
WO2001097843A2 (en) *	2000-06-22	2001-12-27	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA03002890A (es) *	2000-10-02	2004-12-03	Glaxosmithkline Biolog Sa	Preparacion de virus con envolvente dividido.
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20030162734A1 (en) *	2001-06-28	2003-08-28	Miller Carol A.	Modulation of DENN-MADD expression and interactions for treating neurological disorders
CA2388049A1 (en) *	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
EP1537214B1 (de) *	2002-09-01	2006-03-01	Washington University	Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
GB0304424D0 (en) *	2003-02-26	2003-04-02	Glaxosmithkline Biolog Sa	Novel compounds
US20060193821A1 (en) *	2004-03-05	2006-08-31	Diener John L	Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
CA2572427A1 (en) *	2004-07-18	2006-01-18	Heather L. Davis	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US8110196B2 (en) *	2005-04-29	2012-02-07	Polytopas LLC	Methods and compositions for polytopic vaccination

1997
- 1997-01-28 CA CA2244946A patent/CA2244946C/en not_active Expired - Lifetime
- 1997-01-28 EP EP97903998A patent/EP0879284B1/de not_active Revoked
- 1997-01-28 DE DE69739515T patent/DE69739515D1/de not_active Revoked
- 1997-01-28 WO PCT/US1997/001277 patent/WO1997028259A1/en not_active Ceased
- 1997-01-28 JP JP52775297A patent/JP4359654B2/ja not_active Expired - Lifetime
- 1997-01-28 AT AT97903998T patent/ATE437943T1/de not_active IP Right Cessation
2001
- 2001-09-04 US US09/947,209 patent/US20030203861A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2244946A1 (en)	1997-08-07
JP4359654B2 (ja)	2009-11-04
EP0879284A1 (de)	1998-11-25
EP0879284B1 (de)	2009-07-29
JP2000503853A (ja)	2000-04-04
CA2244946C (en)	2010-04-13
US20030203861A1 (en)	2003-10-30
WO1997028259A1 (en)	1997-08-07
DE69739515D1 (de)	2009-09-10
EP0879284A4 (de)	2002-05-29

Legal Events

Date	Code	Title	Description
2010-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69739515D1 (de)	2009-09-10	Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
KR102858623B1 (ko)	2025-09-10	신규 인공 핵산 분자
Ulmer et al.	1996	DNA vaccines
EP3452493B1 (de)	2025-01-15	Nukleinsäuremoleküle und verwendungen davon
JP5931120B2 (ja)	2016-06-08	哺乳動物において免疫を賦活する応答を提供または増強するための複合化された（ｍ）ＲＮＡと裸のｍＲＮＡとを含んでいる組成物、およびその使用
AU7690898A (en)	1998-12-11	Vectors and methods for immunization or therapeutic protocols
WO2002061113A3 (en)	2002-12-12	Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
BR0010361A (pt)	2003-06-10	Seq ências genÈmicas de neisseria e uso destas
US20190160164A1 (en)	2019-05-30	Rotavirus vaccines
NO975730L (no)	1998-02-05	Metode for ökning av beskyttende immunresponser
Staib et al.	2003	Improved host range selection for recombinant modified vaccinia virus Ankara
Armengol et al.	2004	The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response
CN105617373B (zh)	2019-07-09	一种疫苗组合物及其制备方法和应用
Yamada et al.	1990	Differentiation of the mumps vaccine strains from the wild viruses by the nucleotide sequences of the P gene
DE69732029D1 (de)	2005-01-27	Dna enthaltende impfstoffen
JP2005532315A5 (de)	2006-06-29
ZA202309287B (en)	2025-03-26	Coronavirus vaccine comprising a mosaic protein
Satya et al.	2003	A pattern matching algorithm for codon optimization and CpG motif-engineering in DNA expression vectors
JP2024542126A (ja)	2024-11-13	自己増幅ｒｎａ組成物及びその使用方法
CN105797152A (zh)	2016-07-27	一种疫苗组合物及其制备方法和应用
JP2002509545A (ja)	2002-03-26	Ｄｎａワクチンを伴うサブミクロン水中油型エマルジョンの使用
Webster	1999	Potential advantages of DNA immunization for influenza epidemic and pandemic planning
IL149415A0 (en)	2002-11-10	Adjuvanted genetic vaccines
HUP0200320A2 (hu)	2002-05-29	Macskaeredetű CD28-at, CD80-at, CD86-ot vagy CTL4-A-t expresszáló rekombináns vírusok és alkalmazásuk
Kebabçıoğlu et al.	2024	Next Generation Vaccines